LABIANA HEALTH S.A.EO-10 (F:8RK) — Market Cap & Net Worth
Market Cap & Net Worth: LABIANA HEALTH S.A.EO-10 (8RK)
LABIANA HEALTH S.A.EO-10 (F:8RK) has a market capitalization of $53.48 Million (€45.75 Million) as of September 20, 2026. Listed on the F stock exchange, this Germany-based company holds position #21751 globally and #1930 in its home market, demonstrating a -6.40% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LABIANA HEALTH S.A.EO-10's stock price €5.85 by its total outstanding shares 8489255 (8.49 Million). Also see LABIANA HEALTH S.A.EO-10 balance sheet assets for a full breakdown of the balance sheet.
LABIANA HEALTH S.A.EO-10 Market Cap History: 2022 to 2026
LABIANA HEALTH S.A.EO-10's market capitalization history from 2022 to 2026. Data shows growth from $30.17 Million to $58.06 Million (24.13% CAGR). Also see LABIANA HEALTH S.A.EO-10 operating cash flow efficiency for how efficiently the company converts equity into cash flow.
LABIANA HEALTH S.A.EO-10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LABIANA HEALTH S.A.EO-10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest LABIANA HEALTH S.A.EO-10 stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.58x
LABIANA HEALTH S.A.EO-10's market cap is 0.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
16.92x
LABIANA HEALTH S.A.EO-10's market cap is 16.92 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $30.17 Million | $57.85 Million | -$8.94 Million | 0.52x | N/A |
| 2023 | $11.71 Million | $58.46 Million | -$4.42 Million | 0.20x | N/A |
| 2024 | $26.80 Million | $66.26 Million | $253.45K | 0.40x | 105.73x |
| 2025 | $43.47 Million | $75.18 Million | $2.57 Million | 0.58x | 16.92x |
Competitor Companies of 8RK by Market Capitalization
Companies near LABIANA HEALTH S.A.EO-10 in the global market cap rankings as of September 20, 2026. Review LABIANA HEALTH S.A.EO-10 tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to LABIANA HEALTH S.A.EO-10 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
LABIANA HEALTH S.A.EO-10 Historical Marketcap From 2022 to 2026
Between 2022 and today, LABIANA HEALTH S.A.EO-10's market cap moved from $30.17 Million to $ 58.06 Million, with a yearly change of 24.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €58.06 Million | +33.56% |
| 2025 | €43.47 Million | +62.22% |
| 2024 | €26.80 Million | +128.81% |
| 2023 | €11.71 Million | -61.18% |
| 2022 | €30.17 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of LABIANA HEALTH S.A.EO-10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $53.48 Million USD |
| MoneyControl | $53.48 Million USD |
| MarketWatch | $53.48 Million USD |
| marketcap.company | $53.48 Million USD |
| Reuters | $53.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LABIANA HEALTH S.A.EO-10
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, North America, and internationally. It offers anesthetics-sedatives, anti-infectives, anti-inflammatories, antiparasitics, hormonals, nutritional products, metabolism regulators, and vitamin products. The company also provides sterile and lyophilized dosage f… Read more